What we do
Access program
In collaboration with the World Health Organization (WHO) and external experts, the Consortium has developed an Access & Delivery strategy that will ensure accessibility and affordability of the potential new treatment option based on an innovative not-for-profit procurement mechanism.
Access and affordability path
- Once approved, the product will be made available on a not-for-profit basis. Together with external stakeholders, the Consortium is exploring not-for-profit procurement models and innovative financing mechanisms to ensure sustainable access to countries.
- To ensure affordability of the product, an equitable pricing strategy was built into the program from the beginning. All Research & Development investments from partners and funders are delinked from the final cost of the product. Stringent manufacturing methods and processes were taken to decrease the Cost of Goods (CoGs) to the minimum.
- To allow for large-scale production of the new product and address the needs of endemic countries in Africa, a partnership with Universal in Kenya was signed and announced in 2021.
- Collaboration with the WHO Essential Medicines List team has been secured. This will help to ensure placement of the potential new treatment option on the Essential Medicines List for Children to facilitate inclusion of the product on National Essential Medicines Lists. Additionally, extensive conversations with various country institutions are ongoing to prepare and facilitate the path of inclusion of the potential new treatment option in their local policy guidelines.